The complaint filed against the NASDAQ-listed firm centers on violations of the Securities Exchange Act of 1934. Litigation attorneys claim that ADMA Biologics artificially inflated its financial performance by utilizing channel stuffing, a practice designed to manufacture the appearance of steady revenue growth. Furthermore, the suit alleges the company failed to maintain the internal controls necessary to provide accurate public disclosures during the specified class period.

Shareholders who incurred financial losses due to these alleged misrepresentations are encouraged to contact Brian Schall at the firm's Los Angeles office. While the class has not yet received formal certification, affected investors retain the option to participate in the recovery effort or remain absent class members. The firm is currently offering consultations to discuss individual rights for those seeking to recover damages stemming from the company's market disclosures.